

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



百信集團
PASHUN GROUP

Pa Shun Pharmaceutical International Holdings Limited

百信藥業國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 574)

**VOLUNTARY ANNOUNCEMENT
INCREASE IN SHAREHOLDING BY
THE CHAIRMAN AND CONTROLLING SHAREHOLDER**

This is a voluntary announcement of Pa Shun Pharmaceutical International Holdings Limited (the “**Company**”). The Company was informed by Mr. Chen Yenfei (“**Mr. Chen**”), the chairman, chief executive officer and controlling shareholder (having the meaning ascribed to it under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited) of the Company, that on 12 April 2017, Praise Treasure Limited, a company wholly-owned by Mr. Chen, entered into a sale and purchase agreement to acquire 6,000,000 shares of the Company, representing 0.6% of the entire issued share capital of the Company as at the date of this announcement (“**Acquisition**”) and completion of the Acquisition is scheduled to take place on 19 April 2017.

Immediately after completion of the Acquisition, Mr. Chen’s shareholding in the Company, through Praise Treasure Limited, will increase from approximately 47.40% to approximately 48.00%.

On behalf of the Board

Pa Shun Pharmaceutical International Holdings Limited

Mr. Chen Yenfei

Chairman and Chief Executive Officer

Hong Kong, 12 April 2017

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yenfei, Mr. Shen Shun, Mr. Zhou Jian; the non-executive directors of the Company are Mr. Li Ho Tan, Mr. Zhang Xiongfeng and Mr. Masahiro Honna; and the independent non-executive directors of the Company are Mr. Liu Liangzhong, Mr. Wong Tak Shing and Mr. Min Feng.